Quantcast

Latest Ketones Stories

2014-09-16 08:32:01

Big Cities Health Coalition Urges Immediate Federal Action WASHINGTON, Sept. 16, 2014 /PRNewswire/ -- Today, the top public health officials from Boston, Chicago, and New York City, all members of the Big Cities Health Coalition, arrived on Capitol Hill with a grim report on the state of opioid addiction and overdose in our nation's cities - and a request for federal action to be taken immediately. "Opioid addiction is one of the most challenging problems for health departments to...

2014-09-16 08:29:45

Results Validating the Multi-Modal Mechanism of Action Would Provide the Basis for Differentiating LevoCap ER from other Pain Therapies NEW YORK, Sept. 16, 2014 /PRNewswire/ -- Relmada Therapeutics, Inc., (OTCBB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has entered into an agreement with Memorial Sloan Kettering Cancer Center (MSKCC) in a series of animal studies for levorphanol, the active ingredient of...

2014-09-15 23:07:16

Market Size - $2.39 Billion in 2013, Market Growth - CAGR of 4.6%, Market Trends – Shift towards adoption of bio-based solvents. View Full Report with TOC - http://www.grandviewresearch.com/industry-analysis/methyl-ethyl-ketone-mek-market San Francisco, California (PRWEB) September 15, 2014 The global MEK market is expected to reach USD 3.26 billion by 2020, according to a new study by Grand View Research, Inc. Growing demand for paints and coatings in infrastructure, automotive and...

2014-09-09 08:31:52

Material Progress on All Fronts in 2014 Leave Company Strongly Positioned to Unlock the Value of its Robust Pain Product Pipeline NEW YORK, Sept. 9, 2014 /PRNewswire/ -- Relmada Therapeutics, Inc., (OTCBB: RLMD), a Nevada corporation (the "Company") developing novel therapies for the treatment of chronic pain, today announced that is has filed its Form 10-K with the SEC, showing the Company's significant strides in 2014. The Company has made significant progress scientifically, financially...

2014-09-08 08:30:58

Studies to Investigate Ability of KP201 to Deter Abuse and Reduce Opioid-Induced Constipation CORALVILLE, Iowa, Sept. 8, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today the initiation of clinical trials of KP201 designed to investigate the drug candidate's ability to deter abuse and reduce opioid-induced constipation. KP201 (benzhydrocodone hydrochloride...

2014-09-04 16:27:27

STAMFORD, Conn., Sept. 4, 2014 /PRNewswire/ -- Purdue Pharma is presenting results from several studies and post-hoc analyses evaluating extended-release, single-entity hydrocodone bitartrate tablets, including the analgesic effectiveness and safety among patients transitioning from immediate-release hydrocodone combination products and the formulation's abuse-deterrent potential in recreational opioid abusers at PAINWeek national conference Sept. 2 - 6 in Las Vegas....

2014-09-03 08:32:49

September 4th ceremony celebrates 2014 accomplishments including FDA approval and anticipated commercial launch of BUNAVAIL RALEIGH, N.C., Sept. 3, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that the company will visit the NASDAQ MarketSite in Times Square on September 4, 2014. In honor of the occasion, Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will ring the opening bell for the trading session that day....

2014-09-02 20:24:44

- Primary efficacy endpoint met with a statistically significant reduction of sIGF-I levels of 26% at the 400mg/week dose (P

2014-09-02 08:31:44

Results presented during ESC Congress 2014 Clinical Trial Update Hot Line session BARCELONA, Spain, Sept. 2, 2014 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced data from a subgroup analysis of the phase 3 ENGAGE AF-TIMI 48 study, that explores the relationship between edoxaban dose, concentration and anti-factor Xa activity in patients with non-valvular atrial fibrillation (NVAF). The analysis also compared rates of major bleeding and...

2014-08-31 23:01:19

Harbor Village Florida Comments on New Street Drug Showing to be Much More Powerful Than Heroin USA (PRWEB) August 31, 2014 According to an article posted in Medical News Today (8/21), entitled Emerging Street Drug Fifteen Times Stronger than Heroin, a new opiate has begun to hit the streets of America which is fifteen times more potent than heroin. Known as acetyl fentanyl, this opiate is a non-medical use drug that has been linked to many overdoses and emergency room visits among opiate...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'